There’s information. And then there’s intelligence.

PharmSource’s accurate, insightful Trend Reports provide context and meaning that’s critical to decision-makers in the bio/pharma contract services arena. Our experts identify trends and forecast changes – delivering the knowledge and understanding necessary to achieve optimal strategic outcomes.

Dose CMOs by the Numbers: Composition, Size, Market Share and Outlook

This proprietary report is based on PharmSource’s expert quantitative analysis of the contract dose manufacturing market. It will help you understand the events behind both organic and inorganic revenue changes.

PharmSource’s experts explain the relative market shares of solid, semi-solid/liquid/injectable and…

Learn more

M&A in the CMC Services Industry: Implications and Outlook

M&A is reshaping the bio/pharmaceutical contract development services industry. Established CMOs and CROs are pursuing acquisitions to drive scale and broaden their offerings, while private equity are anxious to either gain a presence in the industry or cash in on investments already made. Acquisitions of facilities divested by bio/pharma companies offer…

Learn more

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition

40 pages and over 30 tables and graphs

Where’s your place in the CMO hierarchy?
Find out in the CMO industry’s authoritative analysis of manufacturing of NDA approvals. Only CMO Scorecard enables the CMO industry to…

Learn more

Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs.

Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in…

Learn more

Bio/Pharma CapEx Trends 2016

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

Having spent over $150 billion for new plant and equipment in the past 5 years, it’s clear that global bio/pharma companies would rather…

Learn more

Contract Manufacturing Market Opportunities for Antibody Drug Conjugates

This expert trend report is an indispensable resource for understanding the technical developments in the Antibody Drug Conjugate (ADC) sector and the scale of the commercial opportunities and risks for CMOs.

The CDMO sector is investing significant resources to expand its capabilities in the ADC arena. More than 20 companies are active in the sector although, to date, no single company…

Learn more